HYDERABAD : Intranasal vaccines will be game-changer in the fight against covid, said Dr Krishna Ella, chairman of Bharat Biotech.
In an interview, Ella said phase 3 clinical trials of the non-invasive, needle-free vaccine are on, and the initial results are promising.
Once the trials are completed, Hyderabad-based Bharat Biotech will submit the data to the regulator for approval. Ella also spoke about vaccines in the pipeline to be manufactured by Bharat Biotech, including those against Chikungunya and Zika.
The firm is upgrading its manufacturing facilities, specifically for Covaxin, after the World Health Organization (WHO) suspended the vaccine supply through UN procurement agencies.